Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Medical supervision: required
To provide timely, complementary evidence, we conducted a comparison of tirzepatide and semaglutide in patients at low, moderate and high cardiovascular risk who were diagnosed with obesity and type 2 diabetes and subgroups with specific cardiovascular conditions
Manufactured by Novo Nordisk, Rybelsus is the first and only oral GLP-1 receptor agonist for managing type 2 diabetes
Over 68 weeks, those taking semaglutide lost an average of 16.86% of their weight [3]
These usually resolve within hours to a few days
US$ 23.60
US$ 21.10
US$ 28.36
US$ 27.93
US$ 28.86
US$ 28.30
US$ 25.95
US$ 20.62
